Amunix Pharmaceuticals snaps up $117m Series B
Amunix Pharmaceuticals Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has raised $117 million in Series B financing.
Amunix Pharmaceuticals Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has raised $117 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination